Placebo for SAD
Sponsors
Theravance Biopharma, Spero Therapeutics, ZYUS Life Sciences Inc., Innovent Biologics (Suzhou) Co. Ltd., EnnovaBio Australia Pharmaceuticals Pty Ltd
Conditions
Atopic Dermatitis PatientsHealthyHealthy ParticipantsHealthy VolunteersOsteoarthritis
Phase 1
SAD and MAD Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of TD-1473 in Healthy Subjects
CompletedNCT02657122
Start: 2015-12-31End: 2016-04-30Updated: 2021-01-19
A Study of the Safety, Tolerability, and Pharmacokinetics of SPR720 in Healthy Volunteers
CompletedNCT03796910
Start: 2018-12-18End: 2019-09-24Updated: 2019-10-28
Trichomylin® Safety, Tolerability & Pharmacokinetics in Healthy Adults and First in Human Osteoarthritis Pain Evaluation
CompletedNCT04867057
Start: 2021-04-19End: 2022-05-30Updated: 2024-06-27
A First In Human (FIH) Study of IBI356 in Healthy Participants and in Atopic Dermatitis Patients
CompletedNCT06193434
Start: 2024-01-05End: 2025-08-20Updated: 2025-09-02
A First-in-Human SAD/MAD Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ENC1018 in Healthy Adult Subjects
CompletedNCT06224400
Start: 2024-03-05End: 2025-04-15Updated: 2025-04-25